Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

This second trial of COMP360 (psilocybin) by COMPASS will investigate the effectiveness of the psychedelic for anorexia in 60 patients.

The trial is the 7th psychedelic trial for eating disorders and currently the largest.

Topic Eating Disorders
Compound Psilocybin
Country United States of America United Kingdom
Visit trial
Status Not yet recruiting
Results Published
Start date 01 August 2022
End date 01 December 2023
Chance of happening 90%
Phase Phase II
Design Blinded
Type Interventional
Generation Second
Participants 60
Sex All
Age 18- 99
Therapy Yes

Trial Details

This study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa.

NCT Number NCT05481736

Sponsors & Collaborators

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.